Cyclooxygenase enzymes, mainly COX-1 and COX-2, have been shown to contribute to the regulation of inflammation, pain, and physiological homeostasis, positioning them as critical targets for the development of novel anti-inflammatory therapies. Although NSAIDs have proven their efficacy in COX inhibition, their adverse effects have limited their use, highlighting a research gap that necessitates further exploration of natural compounds, such as beta-sitosterol (BS) and astaxanthin (AXT), as potentially safer, selective COX modulators. This study aimed to explore the potential synergistic effects of BS-AXT combination in modulating COX enzymes through molecular docking to discover their combined activity as safer, natural anti-inflammatory agents. Docking results revealed that the BS-AXT combination significantly enhanced the binding affinity of BS to COX-2, improving from -7.5424 kcal/mol (alone) to -9.2033 kcal/mol in the combination form, indicating a potential synergistic interaction. Consistent with previous docking studies, BS and AXT demonstrated similar binding behaviors, dominated by hydrophobic interactions, particularly with key nonpolar residues within the COX-2 active site. In conclusion, the docking results suggest that the BS-AXT combination could be a natural COX-2 selective inhibitor, supporting the need for further studies to confirm its effectiveness and safety.
30 September 2024 in Biomedical and Pharmacology Journal
The aim of the current research was to dock the two abundant bioactive constituents of Polygonum minus leaf extract, in1cluding Quercetin 3-Glucuronide (Miquelianin) and Quercitrin (Quercetin-3-rhamnoside). In-silico Molecular modelling technique was used to predict about a protein (enzyme) interacts with molecules (ligands). Monoamine oxidase-A (MAO-A) is the key enzyme that is involved in the breakdown of neurotransmitters like serotonin and noradrenaline. Drugs that are involved in its inhibition, are considered to be antidepressant agents. This molecular docking study observed the binding energy of selected ligands and their interactions with amino acid residue along with bond types in the MAO-A structure. Molecular docking was done using Molecular Operating Environment (MOE) software, whereas visualization and expression of results were carried out using Discovery Studio (DS) visualizer. Clorgyline was used in this study as a co-crystal ligand, whereas moclobemide was used as a standard MAO-A inhibitor, and Amitriptyline was used as a common antidepressant which also has some MAO-A inhibitory effect. Quercetin 3-glucuronide (Miquelianin) and Quercitrin (Quercetin-3-rhamnoside) have more binding affinities with MAO-A structure as compared to all other drugs. Its interaction pattern was most likely moclobemide and Clorgyline, which are considered standard MAO-A inhibitors in this study. Based on these results, it is concluded that Quercetin 3-Glucuronide (Miquelianin) and Quercitrin (Quercetin-3-rhamnoside) have the potential to become potent MAO-A inhibitors in future.
Depression and anxiety are among the most prevalent mental health disorders, posing significant challenges to individuals and society. Despite the widespread use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), many patients fail to achieve full remission or encounter debilitating side effects. This underscores an urgent need for innovative therapeutic approaches that go beyond traditional monoaminergic systems, targeting new pathways and mechanisms involved in these complex disorders. Recent advances have highlighted promising therapeutic targets, including the glutamatergic system. Ketamine, an NMDA receptor antagonist, has demonstrated rapid and sustained improvements in mood, inspiring the development of drugs that modulate glutamate transmission. Other systems, such as neuropeptides like oxytocin and vasopressin, are gaining attention for their roles in emotional regulation, while the endocannabinoid system offers potential for regulating mood and stress response [1]. Another recent study have shown that ketamine may offer significant benefits for individuals with psychiatric conditions such as treatment-resistant bipolar depression. Evidence suggests that even a single dose of intranasal ketamine can produce swift antidepressant effects, offering an alternative option for patients unresponsive to standard treatments [2] These novel approaches bring significant challenges with them. The safety profile of new agents must be rigorously evaluated to avoid unintended consequences, and regulatory barriers can delay the availability of innovative therapies. Moreover, the heterogeneity of depression and anxiety, influenced by genetic, environmental, and social factors, highlights the need for personalised medicine. Future research must prioritise understanding these differences to optimise treatment outcomes for diverse populations. The exploration of novel targets and drugs signals a paradigm shift in the treatment of depression and anxiety, moving away from a one-size-fits-all approach toward tailored interventions. These advancements bring renewed hope to millions of patients worldwide, promising more effective, rapid, and sustainable relief. With ongoing research and careful clinical translation, these innovative therapies have the potential to transform mental health care in the coming decades.